A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors [clinicaltrials:NCT01248949]

Bio2RDF uri

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors [clinicaltrials:NCT01248949]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT01248949

Bio2RDF identifier

NCT01248949

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01248949

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01248949

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

120

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01248949 arm group 0f430f70432cb489778e7e7f18990215 [clinicaltrials_resource:NCT01248949/arm-group/0f430f70432cb489778e7e7f18990215]

NCT01248949 arm group 444925d1e7b7121b3411a981b58be330 [clinicaltrials_resource:NCT01248949/arm-group/444925d1e7b7121b3411a981b58be330]

NCT01248949 arm group 5b1e3d7ca59ab2de754190227756bc2c [clinicaltrials_resource:NCT01248949/arm-group/5b1e3d7ca59ab2de754190227756bc2c]

NCT01248949 arm group 7ec9a64e004e3eb2755033cc8c212a1c [clinicaltrials_resource:NCT01248949/arm-group/7ec9a64e004e3eb2755033cc8c212a1c]

NCT01248949 arm group 9a66ebbe89b3b554c2c57ba41b326aab [clinicaltrials_resource:NCT01248949/arm-group/9a66ebbe89b3b554c2c57ba41b326aab]

NCT01248949 arm group d1f82d052293a1375ff8a9159f089d8f [clinicaltrials_resource:NCT01248949/arm-group/d1f82d052293a1375ff8a9159f089d8f]

NCT01248949 arm group e27070b94dfb9e60213ad4d933479685 [clinicaltrials_resource:NCT01248949/arm-group/e27070b94dfb9e60213ad4d933479685]

NCT01248949 arm group fb2c319a7450b4cb434e0f61e33bb5fc [clinicaltrials_resource:NCT01248949/arm-group/fb2c319a7450b4cb434e0f61e33bb5fc]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

To determine the maximu ...... esistant to standard therapy.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Study to Evaluate the Safety ...... cts With Advanced Solid Tumors

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI3617 Up until 90 days after the last dose of MED3617 [clinicaltrials_resource:f1563025a812680089289060cf4656f0]

Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI3617 Up until 90 days after the last dose of MED3617 [clinicaltrials_resource:ffda67b2608c4a003406e93ffcc05edb]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI3617 Up until 90 days after the last dose of MED3617 [clinicaltrials_resource:12bb4154d7e29c787933199ee3d80503]

Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI3617 Up until 90 days after the last dose of MED3617 [clinicaltrials_resource:2192fd8b59586e1d9194eef73e0b5b95]

Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI3617 Up until 90 days after the last dose of MED3617 [clinicaltrials_resource:45ff360b5cb5328e11886fb72c9ea1f9]

Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI3617 Up until 90 days after the last dose of MED3617 [clinicaltrials_resource:a01e44a58a3cce369dc40eab464722a3]

Determine the maximum tolerable dose (MTD) or optimal biological dose (OBD) of MEDI3617 Up until 90 days after the last dose of MED3617 [clinicaltrials_resource:ee8578e16d05befe9baf0c880757afff]

completion date [clinicaltrials_vocabulary:completion-date]

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01248949 [clinicaltrials_resource:fb22bb2080ccbe693f378f366c51932d]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2010-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

MEDI3617 + Weekly Pax Dose Escalation [clinicaltrials_resource:124050a78fd6bf1b7b3a90368194d415]

MEDI3617 + Bev Q3W Dose Escalation [clinicaltrials_resource:1309959fd3658c2722eadef982217fd9]

Advanced Recurrent Ovarian Tumors [clinicaltrials_resource:1863db95c9dbeb329d235b27ddf5c91b]

MEDI3617 + Gem & Carbo Q3W Dos Esc [clinicaltrials_resource:2a7a2f8e4fe16c10221157031881c564]

MEDI3617 + Pax & Carbo Q3W Dos Esc [clinicaltrials_resource:66ec7335c9266a52436d393259da3467]

MEDI3617 + Bev Q2W Dose Escalation [clinicaltrials_resource:6ffe6103a27b6b581487f4ef60d7cbdb]

MEDI3617 [clinicaltrials_resource:801fd1538e7d4f71d8b2a7504c987bea]

Optional Dose Expansion [clinicaltrials_resource:eb481d3a2a09688c92472927de3fc9f5]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Carboplatin [clinicaltrials_resource:b23f008a3e6b2c8b098db9c0c9a2a2a6]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Advanced recurrent ovarian tumors

http://www.w3.org/2001/XMLSchema#string

Advanced solid tumors

http://www.w3.org/2001/XMLSchema#string

Ang2

http://www.w3.org/2001/XMLSchema#string

MEDI3617

http://www.w3.org/2001/XMLSchema#string

Malignant glioma

http://www.w3.org/2001/XMLSchema#string

Ovarian cancer

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

MedImmune LLC [clinicaltrials_resource:b51d23fca6b91c22d86a173e2ba65c30]

link [clinicaltrials_vocabulary:link]

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product [clinicaltrials_resource:084396fac4ae068b8942452cdbd754c6]

Click here and search for drug information provided by the FDA [clinicaltrials_resource:7a06845f49ed0040937032af97edab4d]

location [clinicaltrials_vocabulary:location]

Research Site [clinicaltrials_resource:d3b83a2f047e1cec01b84754d8ef6a1d]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01248949

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Phase 1/1b, Open-Label, Dose-E ...... cts With Advanced Solid Tumors

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CD-ON-MEDI3617-1043

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

AstraZeneca Clinical Study Information Center [clinicaltrials_resource:10543ee2afbb5dda4b9fa1c83633e27e]

overall official [clinicaltrials_vocabulary:overall-official]

Dominic Lai, MD [clinicaltrials_resource:5f51e2d83d72f96dc8e0a47ec39f9d90]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:965595316c5ae1a4521a298d475eb908]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

MedImmune LLC [clinicaltrials_resource:b51d23fca6b91c22d86a173e2ba65c30]

start date [clinicaltrials_vocabulary:start-date]

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01248949 study design [clinicaltrials_resource:c86f59fc94f368a716081822f37e512e]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01248949

verification date [clinicaltrials_vocabulary:verification-date]

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01248949

http://www.w3.org/2001/XMLSchema#string

title

A Study to Evaluate the Safety ...... cts With Advanced Solid Tumors

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]